drugset
drugset / Trial / NCT06838000

Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents

NCT06838000 ↗

Phase 3 Active not recruiting 1268 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupSingle-blindPrevention

Summary

The purpose of this study is to evaluate the safety and immunogenicity of PCV21 versus 20vPCV ( 20-valent pneumococcal conjugate vaccine, Prevnar 20) for catch-up vaccination in infants (7 to 11 MoA-Months of age), toddlers (12 to 23 MoA), and children/adolescents (2 to 5 YoA and 6 to 17 YoA-years of age).

Timeline

Start
2025-02-28
Primary completion
2026-12-01
Completion
2026-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject 20vPCV Vaccine — Intramuscular
Subject PCV21 Vaccine — Intramuscular

Indications

pneumococcal infection